Attachment: Extract from Clinical Evaluation Pembrolizumab ...

The submission requested a Section 85, Authority Required listing for alectinib for the treatment of patients locally advanced (Stage IIIB) or metastatic (Stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), who have disease progression following treatment with a prior ALK inhibitor. ................
................